Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

House Dust Mite Allergen Reduction in Bedding: Purotex Impregnated Covers of Bekaert Textiles (Purotex covers)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01997606
Recruitment Status : Completed
First Posted : November 28, 2013
Last Update Posted : September 26, 2016
Sponsor:
Collaborator:
Bekaert textiles NV Waregem
Information provided by (Responsible Party):
University Hospital, Ghent

Brief Summary:

Product information:

Purotex is a textile treatment that uses five 100% natural bacteria or probiotics, selected for their ability to clean up house dust mite allergen along with other allergen types.

Study design:

  • Placebo-controlled: the effect of the Purotex impregnated mattress and pillow covers will be compared to untreated, classical bedding covers (placebo).
  • Cross-over design: There will be 2 'treatment' arms. One arm (Arm 1) in which the subjects will first use the Purotex impregnated covers (Set A=Purotex) during 2 months (=period A) and, after a wash out period of 1 month, the untreated covers (set B=placebo) during 2 months (=period B). In the second arm (Arm 2), the subjects will first use the untreated set (set A=placebo) and, after a wash out period the Purotex impregnated covers (set B=Purotex).
  • Randomized: The subjects will be randomly assigned to one of the 2 treatment arms.
  • Double blind: both the subjects and the investigators will not know to which treatment arm the subjects are assigned.

Study hypothesis:

We want to investigate:

  • if there is a reduced concentration of HDM allergen in Purotex covers compared to untreated covers in real life
  • if patients with allergic rhinitis to house dust mite use the Purotex covers, they experience an improvement of their quality of life and sleep, and an improvement of their allergic symptoms and global discomfort

Condition or disease Intervention/treatment Phase
Allergic Rhinitis Other: use of Purotex treated bedding covers Other: placebo Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 20 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Official Title: Cross-over Study of the Impact of Purotex Covers on the Concentration of House Dust Mite Allergen in Bedding and the Quality of Life in Patients With Allergic Rhinitis to House Dust Mite.
Study Start Date : November 2013
Actual Primary Completion Date : September 2016
Actual Study Completion Date : September 2016

Resource links provided by the National Library of Medicine

Drug Information available for: Odactra

Arm Intervention/treatment
Experimental: Purotex
use of Purotex treated bedding covers
Other: use of Purotex treated bedding covers
Purotex is a textile treatment that uses five 100% natural bacteria or probiotics, selected for their ability to clean up house dust mite allergen along with other allergen types. The active probiotics are placed inside of millions of capsules and are introduced during the textile production. These human friendly bacteria remain non-active until friction force is created between the mattress/pillow and the sleeper's body. Under the friction force a small part of the capsules is opened and probiotics become active. They saturate the bacterial capacity of the textile and by doing so, reduce the risk of dust mite allergen development and growth of molds and harmful bacteria. The patients will apply the covers around their mattress and around their pillow. On top of these covers the patients will apply their own fitted sheet and pillowcase (which they will change every 4 weeks).

Placebo Comparator: Placebo
no use of Purotex treated bedding covers
Other: placebo



Primary Outcome Measures :
  1. Change in house dust mite allergen concentration [ Time Frame: every two weeks, starting after randomisation untill completion of the study (5 months after randomisation) ]
    Concentration of house dust mite allergen in dust collected from the mattress and pillow covers will be measured by using ELISA During the study, the patients will collect dust every 2 weeks (for each cover their will be 5 time points with an interval of 2 weeks on which dust will be collected)


Secondary Outcome Measures :
  1. Change in quality of life [ Time Frame: every week during the course of the study (from baseline untill 5 months after) ]
    questionnaires: RQLQ, NRQLQ

  2. change in quality of sleep [ Time Frame: every week during the course of the study (from start till 5 months) ]
  3. change in control of allergic rhinitis symptoms [ Time Frame: every week during the course of the study (from baseline till month 5) ]
    questionnaire

  4. change in global discomfort [ Time Frame: every week during the course of the study (from baseline till month 5) ]
    global discomfort due to allergic symptoms and discomfort from specific symptoms questionnaire VAS

  5. change in use of rescue medication [ Time Frame: every week during the course of the study (from baseline till month 5) ]
    patients will fill out every week a questionnaire about the use of medication for their allergic rhinitis (and asthma)

  6. change in discomfort during sleep [ Time Frame: every week during the course of the study (from baseline till month 5) ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Subjects must be willing to give/sign informed consent
  • Subjects (male or female) must be at least 18 years old and maximum 65 years old at screening
  • Clinical history of allergic rhinitis for at least 1 year
  • Positive skin prick test for D. Pteronyssinus ± D. Farinae
  • Positive nasal provocation test with the house-dust-mite allergen
  • Specific IgE: Unicap positive to D. Pteronyssinus (d1) and D. Farinae (d2) (> 0.7U/ml)
  • VAS score for global discomfort caused by nasal- or other allergic symptoms during the previous 4 weeks ≥ 5.
  • The concentration of Der p1 in the dust collected from own bedding (mattress and pillow), measured by ELISA is above the detection limit (≥ 0.488 ng/ml).

Exclusion Criteria:

  • Patients sensitized to animals should not be included if they are symptomatic upon exposure and regularly exposed to animals: positive SPT to pets and pets at home
  • Patients with an allergy to tree pollen (symptoms during the season + positive skin prick test) should not be included
  • Subject pregnant or lactating
  • Completed allergen specific immunotherapy (SCIT or SLIT) with HDM within the last 5 years
  • SCIT or SLIT during the study period
  • Regular use of oral corticosteroids for exacerbations of asthma
  • Daily use of oral corticosteroids
  • Daily use of cyclosporine or other immunosuppressant drugs
  • Regular use of antibiotics
  • History of anaphylactic reaction to an allergen
  • Severe general diseases (especially cardiopulmonary disease with reduced lung capacity)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01997606


Locations
Layout table for location information
Belgium
Ghent University Hospital
Ghent, Belgium, 9000
Sponsors and Collaborators
University Hospital, Ghent
Bekaert textiles NV Waregem
Layout table for additonal information
Responsible Party: University Hospital, Ghent
ClinicalTrials.gov Identifier: NCT01997606    
Other Study ID Numbers: 2012/398
First Posted: November 28, 2013    Key Record Dates
Last Update Posted: September 26, 2016
Last Verified: September 2016
Additional relevant MeSH terms:
Layout table for MeSH terms
Rhinitis
Rhinitis, Allergic
Nose Diseases
Respiratory Tract Diseases
Respiratory Tract Infections
Otorhinolaryngologic Diseases
Respiratory Hypersensitivity
Hypersensitivity, Immediate
Hypersensitivity
Immune System Diseases